Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects

Trial Profile

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Fluart Innovative Vaccines; Omninvest
  • Most Recent Events

    • 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-002379-32).
    • 22 Aug 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top